Cargando…

Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19

BACKGROUND: Thromboembolic disease is common in coronavirus disease-2019 (COVID-19). There is limited evidence on the association of in-hospital anticoagulation (AC) with outcomes and postmortem findings. OBJECTIVES: The purpose of this study was to examine association of AC with in-hospital outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Nadkarni, Girish N., Lala, Anuradha, Bagiella, Emilia, Chang, Helena L., Moreno, Pedro R., Pujadas, Elisabet, Arvind, Varun, Bose, Sonali, Charney, Alexander W., Chen, Martin D., Cordon-Cardo, Carlos, Dunn, Andrew S., Farkouh, Michael E., Glicksberg, Benjamin S., Kia, Arash, Kohli-Seth, Roopa, Levin, Matthew A., Timsina, Prem, Zhao, Shan, Fayad, Zahi A., Fuster, Valentin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier on behalf of the American College of Cardiology Foundation 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449655/
https://www.ncbi.nlm.nih.gov/pubmed/32860872
http://dx.doi.org/10.1016/j.jacc.2020.08.041
_version_ 1783574669987676160
author Nadkarni, Girish N.
Lala, Anuradha
Bagiella, Emilia
Chang, Helena L.
Moreno, Pedro R.
Pujadas, Elisabet
Arvind, Varun
Bose, Sonali
Charney, Alexander W.
Chen, Martin D.
Cordon-Cardo, Carlos
Dunn, Andrew S.
Farkouh, Michael E.
Glicksberg, Benjamin S.
Kia, Arash
Kohli-Seth, Roopa
Levin, Matthew A.
Timsina, Prem
Zhao, Shan
Fayad, Zahi A.
Fuster, Valentin
author_facet Nadkarni, Girish N.
Lala, Anuradha
Bagiella, Emilia
Chang, Helena L.
Moreno, Pedro R.
Pujadas, Elisabet
Arvind, Varun
Bose, Sonali
Charney, Alexander W.
Chen, Martin D.
Cordon-Cardo, Carlos
Dunn, Andrew S.
Farkouh, Michael E.
Glicksberg, Benjamin S.
Kia, Arash
Kohli-Seth, Roopa
Levin, Matthew A.
Timsina, Prem
Zhao, Shan
Fayad, Zahi A.
Fuster, Valentin
author_sort Nadkarni, Girish N.
collection PubMed
description BACKGROUND: Thromboembolic disease is common in coronavirus disease-2019 (COVID-19). There is limited evidence on the association of in-hospital anticoagulation (AC) with outcomes and postmortem findings. OBJECTIVES: The purpose of this study was to examine association of AC with in-hospital outcomes and describe thromboembolic findings on autopsies. METHODS: This retrospective analysis examined the association of AC with mortality, intubation, and major bleeding. Subanalyses were also conducted on the association of therapeutic versus prophylactic AC initiated ≤48 h from admission. Thromboembolic disease was contextualized by premortem AC among consecutive autopsies. RESULTS: Among 4,389 patients, median age was 65 years with 44% women. Compared with no AC (n = 1,530; 34.9%), therapeutic AC (n = 900; 20.5%) and prophylactic AC (n = 1,959; 44.6%) were associated with lower in-hospital mortality (adjusted hazard ratio [aHR]: 0.53; 95% confidence interval [CI]: 0.45 to 0.62 and aHR: 0.50; 95% CI: 0.45 to 0.57, respectively), and intubation (aHR: 0.69; 95% CI: 0.51 to 0.94 and aHR: 0.72; 95% CI: 0.58 to 0.89, respectively). When initiated ≤48 h from admission, there was no statistically significant difference between therapeutic (n = 766) versus prophylactic AC (n = 1,860) (aHR: 0.86; 95% CI: 0.73 to 1.02; p = 0.08). Overall, 89 patients (2%) had major bleeding adjudicated by clinician review, with 27 of 900 (3.0%) on therapeutic, 33 of 1,959 (1.7%) on prophylactic, and 29 of 1,530 (1.9%) on no AC. Of 26 autopsies, 11 (42%) had thromboembolic disease not clinically suspected and 3 of 11 (27%) were on therapeutic AC. CONCLUSIONS: AC was associated with lower mortality and intubation among hospitalized COVID-19 patients. Compared with prophylactic AC, therapeutic AC was associated with lower mortality, although not statistically significant. Autopsies revealed frequent thromboembolic disease. These data may inform trials to determine optimal AC regimens.
format Online
Article
Text
id pubmed-7449655
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Published by Elsevier on behalf of the American College of Cardiology Foundation
record_format MEDLINE/PubMed
spelling pubmed-74496552020-08-27 Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19 Nadkarni, Girish N. Lala, Anuradha Bagiella, Emilia Chang, Helena L. Moreno, Pedro R. Pujadas, Elisabet Arvind, Varun Bose, Sonali Charney, Alexander W. Chen, Martin D. Cordon-Cardo, Carlos Dunn, Andrew S. Farkouh, Michael E. Glicksberg, Benjamin S. Kia, Arash Kohli-Seth, Roopa Levin, Matthew A. Timsina, Prem Zhao, Shan Fayad, Zahi A. Fuster, Valentin J Am Coll Cardiol Original Investigation BACKGROUND: Thromboembolic disease is common in coronavirus disease-2019 (COVID-19). There is limited evidence on the association of in-hospital anticoagulation (AC) with outcomes and postmortem findings. OBJECTIVES: The purpose of this study was to examine association of AC with in-hospital outcomes and describe thromboembolic findings on autopsies. METHODS: This retrospective analysis examined the association of AC with mortality, intubation, and major bleeding. Subanalyses were also conducted on the association of therapeutic versus prophylactic AC initiated ≤48 h from admission. Thromboembolic disease was contextualized by premortem AC among consecutive autopsies. RESULTS: Among 4,389 patients, median age was 65 years with 44% women. Compared with no AC (n = 1,530; 34.9%), therapeutic AC (n = 900; 20.5%) and prophylactic AC (n = 1,959; 44.6%) were associated with lower in-hospital mortality (adjusted hazard ratio [aHR]: 0.53; 95% confidence interval [CI]: 0.45 to 0.62 and aHR: 0.50; 95% CI: 0.45 to 0.57, respectively), and intubation (aHR: 0.69; 95% CI: 0.51 to 0.94 and aHR: 0.72; 95% CI: 0.58 to 0.89, respectively). When initiated ≤48 h from admission, there was no statistically significant difference between therapeutic (n = 766) versus prophylactic AC (n = 1,860) (aHR: 0.86; 95% CI: 0.73 to 1.02; p = 0.08). Overall, 89 patients (2%) had major bleeding adjudicated by clinician review, with 27 of 900 (3.0%) on therapeutic, 33 of 1,959 (1.7%) on prophylactic, and 29 of 1,530 (1.9%) on no AC. Of 26 autopsies, 11 (42%) had thromboembolic disease not clinically suspected and 3 of 11 (27%) were on therapeutic AC. CONCLUSIONS: AC was associated with lower mortality and intubation among hospitalized COVID-19 patients. Compared with prophylactic AC, therapeutic AC was associated with lower mortality, although not statistically significant. Autopsies revealed frequent thromboembolic disease. These data may inform trials to determine optimal AC regimens. Published by Elsevier on behalf of the American College of Cardiology Foundation 2020-10-20 2020-08-26 /pmc/articles/PMC7449655/ /pubmed/32860872 http://dx.doi.org/10.1016/j.jacc.2020.08.041 Text en © 2020 Published by Elsevier on behalf of the American College of Cardiology Foundation. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Investigation
Nadkarni, Girish N.
Lala, Anuradha
Bagiella, Emilia
Chang, Helena L.
Moreno, Pedro R.
Pujadas, Elisabet
Arvind, Varun
Bose, Sonali
Charney, Alexander W.
Chen, Martin D.
Cordon-Cardo, Carlos
Dunn, Andrew S.
Farkouh, Michael E.
Glicksberg, Benjamin S.
Kia, Arash
Kohli-Seth, Roopa
Levin, Matthew A.
Timsina, Prem
Zhao, Shan
Fayad, Zahi A.
Fuster, Valentin
Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19
title Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19
title_full Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19
title_fullStr Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19
title_full_unstemmed Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19
title_short Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19
title_sort anticoagulation, bleeding, mortality, and pathology in hospitalized patients with covid-19
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449655/
https://www.ncbi.nlm.nih.gov/pubmed/32860872
http://dx.doi.org/10.1016/j.jacc.2020.08.041
work_keys_str_mv AT nadkarnigirishn anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT lalaanuradha anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT bagiellaemilia anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT changhelenal anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT morenopedror anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT pujadaselisabet anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT arvindvarun anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT bosesonali anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT charneyalexanderw anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT chenmartind anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT cordoncardocarlos anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT dunnandrews anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT farkouhmichaele anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT glicksbergbenjamins anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT kiaarash anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT kohlisethroopa anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT levinmatthewa anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT timsinaprem anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT zhaoshan anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT fayadzahia anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19
AT fustervalentin anticoagulationbleedingmortalityandpathologyinhospitalizedpatientswithcovid19